

EVGEN PHARMA PLC

Investor Symposium

18 September 2018



Disclaimer

This document has been prepared by, and is the sole responsibility of Evgen Pharma plc (the "Company" or "Evgen") which trades on the AIM market of the London Stock Exchange under ticker EVG.

By attending this presentation and/or reviewing the slides, you agree to be bound by the following conditions. The information and opinions contained in this presentation have not been independently verified, are provided as at the date hereof and are subject to amendment, revision and completion without notice. No person is under any obligation to update or keep current the information contained in this presentation. No representation, warranty or undertaking, express or implied, is made by the Company, its advisers or representatives, or their respective officers, employees or agents as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or the opinions contained herein. The Company, its advisers or representatives, or their respective officers, employees and agents expressly disclaim any and all liability which may be based on this and any errors therein or omissions therefrom.

This document is not an admission document or a prospectus. This document does not constitute or form any part of any offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any shares in the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract therefor. This document has not been authorised or approved for the purposes of section 21 of the Financial Services and Markets Act 2000 and accordingly it is a communication made only to persons who (a) are persons in Member States of the European Economic Area who are qualified investors (within the meaning of article 2(1)(e) of the EU Prospectus Directive (which means Directive 2003/71/EC as amended, and includes the 2010 PD Amending Directive (Directive 2010/73/EU) to the extent implemented in the relevant Member State) (the "Prospectus Directive") ("Qualified Investors"); and in the United Kingdom, are Qualified Investors and who (i) fall within one or more of the exemptions from section 21 of FSMA contained in articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (which includes persons who are authorised or exempt persons within the meaning of FSMA, certain other investment professionals, high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts) and/or (ii) are persons who are otherwise permitted by law to receive it ("Relevant Persons"). Any investment or investment activity to which this document relates is only available to Relevant Persons. Persons of any other description, including those who do not have professional experience in matters relating to investments, should not rely on this document or act on its contents for any purpose whatsoever and should return it to the Company immediately.

If you are in any doubt about the contents of this document, you should consult a person authorised under the Financial Services and Markets Act 2000 who specialises in advising on the acquisition of shares and securities of unlisted companies. You should be aware that an investment in the Company involves a high degree of risk and investors should be aware of such risks and should rely on their own examination of the Company and make the decision to invest only after careful consideration and, if appropriate, consultation with an independent financial adviser. Any investment or investment activity to which this document relates is only available to Relevant Persons. Persons of any other description should not rely on this document or act on its contents for any purpose whatsoever and should return it to the Company immediately.

The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions. Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been verified by the Company or any other person. Accordingly no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation and no reliance should be placed on such information or opinions. None of the Company, or any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation. No part of this presentation, or the fact of its distribution, should form the basis of or be relied upon in connection with any contract or commitment or investment decision whatsoever.

Recipients of this presentation are not to construe its contents, or any prior or subsequent communications from or with the Company or its representatives as investment, legal or tax advice. In addition, this presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of the Company or any transaction to be entered into by any member of the Evgen group. No undertaking, representation or warranty, express or implied, is given by the Company, any member of the Evgen group, or any of their respective current or proposed directors, officers, partners, employees, secondees, agents or advisers or any other person as to the accuracy or completeness of the information or as to the opinions contained in this document and no liability is accepted for any such information or opinions. Further, the information in this presentation is not complete and may be changed. Recipients of this presentation should each make their own independent evaluation of the information and of the relevance and adequacy of the information in this document and should make such other investigations as they deem necessary.

This presentation may contain forward-looking statements that reflect the Company's current views and expectations regarding future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "envisages", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "could", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward looking statements. These forward-looking statements include matters that are not historical facts and speak only as of the date of this document. They appear in a number of places throughout this document and include statements regarding the Company and the directors, and the directors' current intentions, beliefs or expectations concerning, amongst other things, to management's strategic vision, aims and objectives, the conduct of clinical trials, the filing dates for product licence applications and the anticipated launch of specified products in various markets, the Company's ability to find partners for the development and commercialisation of its products as well as the terms for such partnerships, anticipated levels of demand for existing products and products in development, the effect of competition, anticipated efficiencies, trends in results of operations, margins, the overall pharmaceutical market and exchange rates, are all forward looking in nature.

By attending this presentation and/or accepting a copy of this document, you agree to be bound by the foregoing limitations and, in particular, will be taken to have represented, warranted and undertaken that you have read and agree to comply with the contents of this notice including without limitation the obligation to keep this presentation and its contents confidential.

Company summary

- Clinical stage drug development company with a new class of pharmaceuticals
- Based in Cheshire (UK) and listed on AIM (LSE: EVG)
- Focused on the development of well-tolerated, stable, sulforaphane-based compounds that:
 - *inhibit the STAT3 pathway – a target for reducing cancer proliferation and metastases; and*
 - *activate the Nrf2 pathway – a target for reducing neurodegeneration*
- Lead product, SFX-01, is in two Phase II trials (oncology and neurology) utilising two separate mechanistic targets with expected read-outs around the end of 2018
- Worldwide exclusive licence to an IP estate covering composition, manufacturing and a series of novel derivatives of sulforaphane, asserting a leadership position around this new class of pharmaceuticals
- Business model looks to partner post-Phase II or potentially post-Phase III (for orphan indications)

Evgen Pharma history

- 1992 Professor Paul Talalay elucidates structure and anti-cancer activity of sulforaphane
- 2008 Company founded to undertake a global hunt for new healthcare technologies
- 2009 Sulforaphane stabilisation technology selected and held under an option agreement
- 2010 Development of the business plan for a new pharmaceutical business
- 2011 First material venture capital investment, option exercised and technology in-licensed
- 2013 CTA-enabling preclinical toxicology package completed
- 2013/14 Two Phase I trials in healthy human volunteers on SFX-01
- 2015 IPO on AIM
- 2015 In-license sulforaphane analogues from University of Seville
- 2016 Two Phase II trials commenced on SFX-01: breast cancer and stroke
- 2018/19 Results of the first two Phase II trials

Objectives of the Investor Symposium

To present an opportunity to engage with independent experts and Evgen to help:

- frame the significance of the two clinical read-outs around the end of the year
- understand the other opportunities in addition to the two lead clinical programmes

The Programme

Time	Title	Speaker	Company / Institution
9.15am	Welcome	Dr Stephen Franklin	Evgen Pharma
9.25am	Biotech investment market and Evgen Pharma plc	Vadim Alexandre	Northland Capital
9.45am	The Science behind Sulforaphane	Prof Albena Dinkova-Kostova	University of Dundee
10.15am	Break (10min)		
10.25am	The STEM trial in breast cancer	Dr Sacha Howell	The Christie Hospital, Manchester
10.55am	The SAS trial in haemorrhagic stroke Overview of preclinical pipeline	Sally Ross	Evgen Pharma
11.35am	Q&A Panel	All speakers	-
12.00pm	Close		